Endometrial endometrioid carcinoma metastases show decreased ER-alpha and PR-A expression compared to matched primary tumors

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Bartosch, Carla ^a,b   Monteiro Reis, Sara ^a   Vieira, Renata ^a   Pereira, Armindo ^c   Rodrigues, Marta ^c   Jerónimo, Carmen ^a,d   Lopes, José M ^b,c,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b University of Porto   (Portugal)

^c Universidade do Porto   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR A; PROTEIN P53; ESTROGEN RECEPTOR ALPHA, HUMAN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOMETRIAL ENDOMETRIOID CARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; METASTASIS; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; RETROSPECTIVE STUDY; COMPARATIVE STUDY; DNA METHYLATION; ENDOMETRIUM TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY;

CARCINOMA, ENDOMETRIOID; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84941985240     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134969     Document Type: Article

References (49)

1. Chi DS, Barakat RR, Palayekar MJ, Levine DA, Sonoda Y, Alektiar K, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2008; 18(2):269-73. doi: 10.1111/j.1525-1438.2007. 00996.x PMID: 18334008.
2. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. The Lancet Oncology. 2012; 13(8):e353-61. doi: 10.1016/S1470-2045(12)70213-9 PMID: 22846840.
3. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2006; 95 Suppl 1:S105-43. doi: 10.1016/S0020-7292(06)60031-3 PMID: 17161155.
4. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. Available: http://seer.cancer.gov/csr/1975-2008/.
5. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2007; 17(5):964-78. doi: 10.1111/j.1525-1438.2007.00897.x PMID: 17442022.
6. Trovik J, Wik E, Werner HM, Krakstad C, Helland H, Vandenput I, et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer. 2013; 49(16):3431-41. doi: 10.1016/j.ejca.2013.06.016 PMID: 23932335.
7. Huvila J, Talve L, Carpen O, Edqvist PH, Ponten F, Grenman S, et al. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2013; 130(3):463-9. doi: 10.1016/j.ygyno.2013.06.015 PMID: 23777659.
8. Hori M, Iwasaki M, Shimazaki J, Inagawa S, Itabashi M. Assessment of hypermethylated DNA in two promoter regions of the estrogen receptor alpha gene in human endometrial diseases. Gynecol Oncol. 2000; 76(1):89-96. doi: 10.1006/gyno.1999.5662 PMID: 10620447.
9. Navari JR, Roland PY, Keh P, Salvesen HB, Akslen LA, Iversen OE, et al. Loss of estrogen receptor (ER) expression in endometrial tumors is not associated with de novo methylation of the 5' end of the ER gene. Clin Cancer Res. 2000; 6(10):4026-32. PMID: 11051252.
10. Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S, Dahiya R. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res. 2001; 61(1):97-102. PMID: 11196205.
11. Xiong Y, Dowdy SC, Gonzalez Bosquet J, Zhao Y, Eberhardt NL, Podratz KC, et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol. 2005; 99(1):135-41. doi: 10.1016/j.ygyno.2005.05.035 PMID: 16024066.
12. Ren Y, Liu X, Ma D, Feng Y, Zhong N. Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer genetics and cytogenetics. 2007; 175(2):107-16. doi: 10.1016/j.cancergencyto.2007.02.002 PMID: 17556066.
13. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science. 2000; 289(5485):1751-4. PMID: 10976068.
14. Miyamoto T, Watanabe J, Hata H, Jobo T, Kawaguchi M, Hattori M, et al. Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma. J Steroid Biochem Mol Biol. 2004; 92 (3):111-8. doi: 10.1016/j.jsbmb.2004.07.007 PMID: 15555905.
15. Jongen V, Briet J, de Jong R, ten Hoor K, Boezen M, van der Zee A, et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 2009; 112(3):537-42. doi: 10.1016/j.ygyno.2008.10.032 PMID: 19108875.
16. Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, et al. The expression ratios of estrogen receptor alpha (ERalpha) to estrogen receptor beta1 (ERbeta1) and ERalpha to ERbeta2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol. 2013; 44(6):1047-54. doi: 10.1016/j.humpath.2012.09.007 PMID: 23266443.
17. Santacana M, Yeramian A, Velasco A, Bergada L, Gatius S, Garcia V, et al. Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia. Histopathology. 2012; 60(3):460-71. doi: 10.1111/j.1365-2559.2011.04106.x PMID: 22276609.
18. Soslow RA, Wethington SL, Cesari M, Chiappetta D, Olvera N, Shia J, et al. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. The American journal of surgical pathology. 2012; 36(12):1771-81. doi: 10.1097/PAS.0b013e318273591a PMID: 23154767.
19. Tangen IL, Werner HM, Berg A, Halle MK, Kusonmano K, Trovik J, et al. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer. 2014; 50(17):3003-10. doi: 10.1016/j.ejca.2014.09.003 PMID: 25281525.
20. Jeronimo C, Monteiro P, Henrique R, Dinis-Ribeiro M, Costa I, Costa VL, et al. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast cancer research and treatment. 2008; 109(1):27-34. PMID: 17549626
21. Ehrlich M, Woods CB, Yu MC, Dubeau L, Yang F, Campan M, et al. Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors. Oncogene. 2006; 25(18):2636-45. doi: 10.1038/sj.onc.1209145 PMID: 16532039; PubMed Central PMCID: PMC1449872.
22. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001; 61(8):3410-8. PMID: 11309301.
23. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. The Journal of molecular diagnostics: JMD. 2006; 8(2):209-17. doi: 10.2353/jmoldx.2006.050135 PMID: 16645207; PubMed Central PMCID: PMC1867588.
24. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annual review of pathology. 2013; 8:277-302. doi: 10.1146/annurev-pathol-020712-163923 PMID: 23092187.
25. Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, et al. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast cancer research: BCR. 2006; 8(3):R31. doi: 10.1186/bcr1508 PMID: 16790076; PubMed Central PMCID: PMC1557736.
26. Penault-Llorca F, Abrial C, Raoelfils I, Chollet P, Cayre A, Mouret-Reynier MA, et al. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. The oncologist. 2008; 13 (12):1235-45. doi: 10.1634/theoncologist.2008-0073 PMID: 19091781.
27. Gallaher J, Anderson AR. Evolution of intratumoral phenotypic heterogeneity: the role of trait inheritance. Interface focus. 2013; 3(4):20130016. doi: 10.1098/rsfs.2013.0016 PMID: 24511380; PubMed Central PMCID: PMC3915835.
28. Calascibetta A, Cabibi D, Rausa L, Aragona F, Barresi E, Martorana A, et al. Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients. Nucleosides, nucleotides & nucleic acids. 2006; 25(9-11):1193-6. doi: 10.1080/15257770600894527 PMID: 17065089.
29. Yano K, Okamura T, Yoshida Y, Ichiyoshi Y, Yasumoto K. Proliferative activity of esophageal carcinomas and their lymph node metastases: comparison using argyrophilic nucleolar organizer region staining. Journal of surgical oncology. 1997; 65(4):274-9. PMID: 9274793.
30. Brodsky AS, Fischer A, Miller DH, Vang S, MacLaughlan S, Wu HT, et al. Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease. PLoS One. 2014; 9(4):e94476. doi: 10.1371/journal.pone.0094476 PMID: 24732363; PubMed Central PMCID: PMC3986100.
31. Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology. 2006; 48(6):674-82. doi: 10.1111/j.1365-2559.2006.02402.x PMID: 16681683.
32. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006; 19(8):1091-100. doi: 10.1038/modpathol.3800620 PMID: 16648864.
33. Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T. Clinical implication of expression of progesterone receptor form A and B mRNAs in secondary spreading of gynecologic cancers. J Steroid Biochem Mol Biol. 1997; 62(5-6):449-54. PMID: 9449248.
34. Fujimoto J, Sakaguchi H, Aoki I, Toyoki H, Tamaya T. Clinical implications of the expression of estrogen receptor-alpha and -beta in primary and metastatic lesions of uterine endometrial cancers. Oncology. 2002; 62(3):269-77. doi: 10.1159/000059575 PMID: 12065875.
35. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2013; 24 (1):101-8. doi: 10.1093/annonc/mds248 PMID: 23002281.
36. Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer treatment reviews. 2012; 38(6):708-14. doi: 10.1016/j.ctrv.2011.11.006 PMID: 22178456.
37. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, et al. Receptor conversion in distant breast cancer metastases. Breast cancer research: BCR. 2010; 12(5): R75. doi: 10.1186/bcr2645 PMID: 20863372; PubMed Central PMCID: PMC3096964.
38. Esteller M. Epigenetics in cancer. N Engl J Med. 2008; 358(11):1148-59. doi: 10.1056/NEJMra072067 PMID: 18337604.
39. Sasaki M, Kotcherguina L, Dharia A, Fujimoto S, Dahiya R. Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. Cancer Res. 2001; 61(8):3262-6. PMID: 11309276.
40. Wen DX, Xu YF, Mais DE, Goldman ME, McDonnell DP. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol. 1994; 14 (12):8356-64. PMID: 7969170; PubMed Central PMCID: PMC359374.
41. Wargon V, Fernandez SV, Goin M, Giulianelli S, Russo J, Lanari C. Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. Breast Cancer Res Treat. 2011; 126(2):319-32. doi: 10.1007/s10549-010-0908-x PMID: 20440553.
42. Smid-Koopman E, Blok LJ, Kuhne LC, Burger CW, Helmerhorst TJ, Brinkmann AO, et al. Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines. J Soc Gynecol Investig. 2003; 10(1):49-57. PMID: 12517594.
43. Dai D, Wolf DM, Litman ES, White MJ, Leslie KK. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 2002; 62(3):881-6. PMID: 11830547.
44. Sakaguchi H, Fujimoto J, Hong BL, Nakagawa Y, Tamaya T. Drastic decrease of progesterone receptor form B but not A mRNA reflects poor patient prognosis in endometrial cancers. Gynecol Oncol. 2004; 93(2):394-9. doi: 10.1016/j.ygyno.2004.01.042 PMID: 15099952.
45. Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res. 1998; 58(9):1860-5. PMID: 9581825.
46. Pijnenborg JM, Romano A, Dam-de Veen GC, Dunselman GA, Fischer DC, Groothuis PG, et al. Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma. J Pathol. 2005; 205(5):597-605. doi: 10.1002/path.1738 PMID: 15726651.
47. De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A. 2002; 99(19):12263-8. doi: 10.1073/pnas.192172299 PMID: 12218173; PubMed Central PMCID: PMC129433.
48. Ghabreau L, Roux JP, Niveleau A, Fontaniere B, Mahe C, Mokni M, et al. Correlation between the DNA global methylation status and progesterone receptor expression in normal endometrium, endometrioid adenocarcinoma and precursors. Virchows Archiv: an international journal of pathology. 2004; 445 (2):129-34. doi: 10.1007/s00428-004-1059-4 PMID: 15221375.
49. Janzen DM, Rosales MA, Paik DY, Lee DS, Smith DA, Witte ON, et al. Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Res. 2013; 73(15):4697-710. doi: 10.1158/0008-5472.CAN-13-0930 PMID: 23744837; PubMed Central PMCID: PMC3752407.